Last week Kyle Bass and Erich Spangenberg, who have upset the pharmaceutical industry by filing more than 30 challenges to issued pharmaceutical patents at the U.S. Patent and Trademark Office, filed two more petitions to invalidate patents owned by two separate pharmaceutical companies. Only this time, the petitions were filed by Bass and Spangenberg as individuals and not by the Coalition for Affordable Drugs, the organization they created earlier this year to challenge pharma patents.
Why the change?
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
